TerminatedPhase 4Results posted

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus

Lead sponsor

GlaxoSmithKline

Asset

Albiglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoints

•Treatment-emergent AEs (any)•Physical Examination Abnormalities•Hematology Values of Potential Clinical Importance (PCI)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02750930

Org study ID204682

Timeline

Milestones

Study first posted2016-04-26estimated

Study start2016-10-07actual

Primary completion2017-03-21actual

Study completion2017-03-21actual

Results first posted2018-03-14actual

Last update posted2019-07-12actual

Assets

Investigational agents

Albiglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects who have completed the 26 week Treatment Phase of Study 200952

•Male or female

•Able and willing to provide informed consent.

Exclusion criteria

•Subject meets one or more of the withdrawal stopping criteria at Visit 1 (Week 26)

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Cardiometabolic biomarkers

2 endpoints

Primary/protocol endpoint/low confidence

Number of Participants With Pulse Rate Values of PCI

Time frame:Up to Week 34

Heart rate, change

threshold achievement, improvement

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	0	-

Primary/protocol endpoint/low confidence

Number of Participants With Systolic and Diastolic Blood Pressure of PCI

Time frame:Up to Week 34

threshold achievement, improvement

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	0	-

Safety / tolerability / PK

7 endpoints

Primary/protocol endpoint

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time frame:Up to Week 34

Treatment-emergent AEs (any)

descriptive

Posted result

Group	Number · Participants	95% CI
Albiglutide LiquidAny SAE	0	-
Any AE	2	-

Primary/protocol endpoint

Number of Participants With Physical Examination Abnormalities

Time frame:Up to Week 34

descriptive

Primary/protocol endpoint

Number of Participants With Hematology Values of Potential Clinical Importance (PCI)

Time frame:Up to Week 34

descriptive

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	1	-

Primary/protocol endpoint

Number of Participants With Clinical Chemistry Parameters of PCI

Time frame:Up to Week 34

threshold achievement, event

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	1	-

Primary/protocol endpoint

Number of Participants With Clinically Significant Urinalysis Abnormalities by Dipstick Method

Time frame:Up to 26 weeks

descriptive

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	0	-

Primary/protocol endpoint

Number of Participants With Clinically Significant Findings for 12-lead ECG

Time frame:Up to Week 34

descriptive

Posted result

Group	Number · Participants	95% CI
Albiglutide Liquid	0	-

Primary/protocol endpoint

Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time

Time frame:Up to Week 34

Immunogenicity (ADA)

threshold achievement, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.